Structure‐Guided Drug Design Targeting Abl Kinase: How Structure and Regulation Can Assist in Designing New Drugs
ChemBioChem · 2024
DOI: 10.1002/cbic.202400296 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift ChemBioChem, 2024. Verfasst von Diego M Martins und 4 weiteren Autor:innen. Beteiligte Einrichtung: Departamento de Química, Instituto de Ciências Exatas, Universidade Federal de Minas Gerais, 31270-901, Pampulha, MG, Brazil. Hauptthemen laut MEDLINE: Protein Kinase Inhibitors, Drug Design, Proto-Oncogene Proteins c-abl. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 214 Literaturangaben. Gefördert von: FAPEMIG (Fundação de Amparo à Pesquisa do Estado de Minas Gerais), FINEP (Brazilian Innovation and Research Funding Agency), CAPES (Coordenação de Aperfeiçoamento de Pessoal de Nível Superior).
Abstract (Originalsprache)
The human protein Abelson kinase (Abl), a tyrosine kinase, plays a pivotal role in developing chronic myeloid leukemia (CML). Abl's involvement in various signaling pathways underscores its significance in regulating fundamental biological processes, including DNA damage responses, actin polymerization, and chromatin structural changes. The discovery of the Bcr‐Abl oncoprotein, resulting from a chromosomal translocation in CML patients, revolutionized the understanding and treatment of the disease. The introduction of targeted therapies, starting with interferon‐alpha and culminating in the development of tyrosine kinase inhibitors (TKIs) like imatinib, significantly improved patient outcomes. However, challenges such as drug resistance and side effects persist, indicating the necessity of research into novel therapeutic strategies. This review describes advancements in Abl kinase inhibitor development, emphasizing rational compound design from structural and regulatory information. Strategies, including bivalent inhibitors, PROTACs, and compounds targeting regulatory domains, promise to overcome resistance and minimize side effects. Additionally, leveraging the intricate structure and interactions of Bcr‐Abl may provide insights into developing inhibitors for other kinases. Overall, this review highlights the importance of continued research into Abl kinase inhibition and its broader implications for therapeutic interventions targeting kinase‐driven diseases. It provides valuable insights and strategies that may guide the development of next‐generation therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Departamento de Química, Instituto de Ciências Exatas, Universidade Federal de Minas Gerais, 31270-901, Pampulha, MG, Brazil.
- Departamento de Produtos Farmacêuticos, Faculdade de Farmácia, Universidade Federal de Minas Gerais, 31270-901, Pampulha, MG, Brazil.
ORCID-Profile: Diego M Martins, Philipe O Fernandes, Lucas A Vieira, Vinícius G Maltarollo, Adolfo H Moraes
Förderung
- FAPEMIG (Fundação de Amparo à Pesquisa do Estado de Minas Gerais)
- FINEP (Brazilian Innovation and Research Funding Agency)
- CAPES (Coordenação de Aperfeiçoamento de Pessoal de Nível Superior)
- CNPq (Conselho Nacional de Desenvolvimento Científico e Tecnológico)
Zitieren
APA
Martins, D. M., Fernandes, P. O., Vieira, L. A., Maltarollo, V. G., & Moraes, A. H. (2024). Structure‐Guided Drug Design Targeting Abl Kinase: How Structure and Regulation Can Assist in Designing New Drugs. ChemBioChem. https://doi.org/10.1002/cbic.202400296
Vancouver
Martins DM, Fernandes PO, Vieira LA, Maltarollo VG, Moraes AH. Structure‐Guided Drug Design Targeting Abl Kinase: How Structure and Regulation Can Assist in Designing New Drugs. ChemBioChem. 2024. doi:10.1002/cbic.202400296
BibTeX
@article{Martins2024,
author = {Martins, Diego M and Fernandes, Philipe O and Vieira, Lucas A and Maltarollo, Vinícius G and Moraes, Adolfo H},
title = {Structure‐Guided Drug Design Targeting Abl Kinase: How Structure and Regulation Can Assist in Designing New Drugs},
journal = {ChemBioChem},
year = {2024},
doi = {10.1002/cbic.202400296}
}
EUVIMED